STOPCAP M1 Programme

Speeding up the evaluation of therapies for metastatic, hormone-sensitive prostate cancer

Speeding up the evaluation of treatments for prostate cancer that has spread beyond the prostate and responds to hormone therapy

What is this study about?

STOPCAP M1 is a worldwide collaborative effort that aims to quickly identify which treatments work best for men with metastatic, hormone sensitive prostate cancer. This will be done through:

1. systematic reviews of treatment effects

2. identification of surrogate outcomes, by trying to find early measurements of prostate cancer control that predict later survival 

3. establishing a repository of patient data which will be used to tackle new questions about advanced prostate cancer and its treatment as they arise. 


More information can be found on the STOPCAP M1 website.

Contact details

Who is funding the study?

The STOPCAP M1 collaboration is funded by Prostate Cancer UK and the Medical Research Council.

When is it taking place?

This programme of research is ongoing.

Where is it taking place?

The programme is led by the MRC Clinical Trials Unit at University College London, and brings together the results of trials carried out worldwide.

Who is included?

Trials that randomised men with metastatic hormone-sensitive prostate cancer.